These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 30047799)

  • 41. Directly observed therapy of chronic hepatitis C with ledipasvir/sofosbuvir in people who inject drugs at risk of nonadherence to direct-acting antivirals.
    Schütz A; Moser S; Schwanke C; Schubert R; Luhn J; Gutic E; Lang T; Schleicher M; Haltmayer H; Gschwantler M
    J Viral Hepat; 2018 Jul; 25(7):870-873. PubMed ID: 29316001
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows.
    Guarino M; Sessa A; Cossiga V; Morando F; Caporaso N; Morisco F;
    World J Gastroenterol; 2018 Jun; 24(24):2582-2595. PubMed ID: 29962815
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lipids, glucose and iron metabolic alterations in chronic hepatitis C after viral eradication - comparison of the new direct-acting antiviral agents with the old regimens.
    Carvalho JR; Velosa J; Serejo F
    Scand J Gastroenterol; 2018; 53(7):857-863. PubMed ID: 29779403
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Improvement of liver stiffness in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response.
    Tada T; Kumada T; Toyoda H; Mizuno K; Sone Y; Kataoka S; Hashinokuchi S
    J Gastroenterol Hepatol; 2017 Dec; 32(12):1982-1988. PubMed ID: 28299813
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cryoglobulinaemic vasculitis in a patient with chronic hepatitis C: favourable outcome due to direct-acting antivirals.
    Boderie MJM; Van Paassen P; Aendekerk JP; Posthouwer D
    Neth J Med; 2020 Sep; 78(5):286-289. PubMed ID: 33093254
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Predictors of functional benefit of hepatitis C therapy in a 'real-life' cohort.
    Steinebrunner N; Stein K; Sandig C; Bruckner T; Stremmel W; Pathil A
    World J Gastroenterol; 2018 Feb; 24(7):852-861. PubMed ID: 29467555
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety and efficacy of direct-acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older.
    Conti F; Brillanti S; Buonfiglioli F; Vukotic R; Morelli MC; Lalanne C; Massari M; Foschi FG; Bernabucci V; Serio I; Prati GM; Negri E; Badia L; Caraceni P; Muratori P; Vitale G; Porro A; Morotti M; Mazzella G; Andreone P
    J Viral Hepat; 2017 Jun; 24(6):454-463. PubMed ID: 27976461
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of hepatitis C virus eradication with direct-acting antivirals on glycidic metabolism.
    Sparvoli JMH; Sparvoli AC; de Carvalho Dumith S; Pereira AA; de Paula ALM; Garcia L; Belarmino V; da Hora VP; de Martínez AMB; Gonçalves CV
    Arch Endocrinol Metab; 2023 Mar; 67(3):314-322. PubMed ID: 36468927
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The impact of directly acting antivirals on the enzymatic liver function of liver transplant recipients with recurrent hepatitis C.
    Raschzok N; Schott E; Reutzel-Selke A; Damrah I; Gül-Klein S; Strücker B; Sauer IM; Pratschke J; Eurich D; Stockmann M
    Transpl Infect Dis; 2016 Dec; 18(6):896-903. PubMed ID: 27632190
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Chronic Hepatitis C Treatment with Direct-Acting Antiviral Agents in a Real-Life Setting.
    Chirino-Sprung RA; Dehesa M; Wolpert E; Corona-Lau C; García-Juarez I; Sánchez-Ávila JF; Moctezuma-Velázquez C; Kershenobich D
    Rev Invest Clin; 2016; 68(4):203-12. PubMed ID: 27623039
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Optimal management of patients with chronic hepatitis C and comorbidities.
    Boccaccio V; Bruno S
    Liver Int; 2015 Jan; 35 Suppl 1():35-43. PubMed ID: 25529086
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice.
    Sarrazin C
    J Hepatol; 2016 Feb; 64(2):486-504. PubMed ID: 26409317
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ribavirin steady-state plasma level is a predictor of sustained virological response in hepatitis C-infected patients treated with direct-acting antivirals.
    van Tilborg M; Lieveld FI; Smolders EJ; van Erpecum KJ; de Kanter CTMM; Maan R; van der Valk M; Arends JE; Dofferhoff ASM; Blokzijl H; Bijmolen M; Drenth JPH; de Knegt RJ; Burger DM;
    Aliment Pharmacol Ther; 2017 Nov; 46(9):864-872. PubMed ID: 28881031
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Daclatasvir, asunaprevir and beclabuvir fixed-dose combination for patients with genotype 1 chronic hepatitis C.
    Thiam A; Conway B
    Drugs Today (Barc); 2018 Apr; 54(4):237-244. PubMed ID: 29869645
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cardiovascular Manifestations of Hepatitis C Virus.
    Goossens N; Negro F
    Clin Liver Dis; 2017 Aug; 21(3):465-473. PubMed ID: 28689586
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin.
    Harrison SA; Hamzeh FM; Han J; Pandya PK; Sheikh MY; Vierling JM
    Hepatology; 2012 Aug; 56(2):464-73. PubMed ID: 22334369
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection.
    Zoulim F; Moreno C; Lee SS; Buggisch P; Horban A; Lawitz E; Corbett C; Lenz O; Fevery B; Verbinnen T; Shukla U; Jessner W
    Virol J; 2018 Jan; 15(1):26. PubMed ID: 29378602
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Interferon-free therapies for patients with chronic hepatitis C genotype 3 infection: A systematic review.
    Gimeno-Ballester V; Buti M; San Miguel R; Riveiro M; Esteban R
    J Viral Hepat; 2017 Nov; 24(11):904-916. PubMed ID: 27925386
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The influence of immunosuppressants on direct-acting antiviral therapy is dependent on the hepatitis C virus genotype.
    Frey A; Piras-Straub K; Walker A; Timm J; Gerken G; Herzer K
    Transpl Infect Dis; 2018 Feb; 20(1):. PubMed ID: 29111569
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Association between ribavirin plasma concentration and sustained virologic response in treatment of patients with genotype 1b chronic hepatitis C with pegylated interferon-α-2b and ribavirin].
    Wang MR; Zhang X; Yang ZG; Li P; Gao L; Chen XH; Wang J; Xiong X; Wang SM; Geng JB; Hao KY; Xie F; Wang M; Zheng WK
    Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):175-80. PubMed ID: 27095759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.